1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Association, 1994.

2. Ammon HPT, Bieck PR, Mandalaz D, Verspohl EJ. Adaptation of blood pressure to continuous heavy coffee drinking in young volunteers. A double-blind crossover study. Br J Clin Pharmacol 1983;15:701-706.

3. Atkinson J, Enslen M. Self-administration of caffeine by the rat. Arzneimittelforschung 1976;26:2059-2061.

4. Austin GA. Perspectives on the history of psychoactive substance use. In: NIDA research issues, vol 24. DHEW publication (ADM) 79-810. Washington, DC: US Government Printing Office, 1979;50-66.

5. Beecher HK. Measurement of subjective responses: quantitative effects of drugs. New York: Oxford University Press, 1959.

6. Bickel WK, Hughes JR, DeGrandpre RJ, Higgins ST, Rizzuto P. Behavioral economics of drug self-administration. IV. The effects of response requirement on the consumption of and interaction between concurrently available coffee and cigarettes. Psychopharmacology (Berlin) 1992;107:211-216.

7. Bigelow GE, Griffiths RR, Liebson I. Experimental human drug self-administration: methodology and application to the study of sedative abuse. Pharmacol Rev 1976;27:523-531.

8. Bonnet MH, Arand DL. Caffeine use as a model of acute and chronic insomnia. Sleep 1992;15:526-536.

9. Boulenger JP, Uhde TW, Wolff EAI, Post RM. Increased sensitivity to caffeine in patients with panic disorders: preliminary evidence. Arch Gen Psychiatry 1984;41:1067-1071.

10. Bozarth MA, ed. Methods of assessing the reinforcing properties of abused drugs. New York: Springer-Verlag, 1987.

11. Bozarth MA. An overview of assessing drug reinforcement. In: Bozarth MA, ed. Methods of assessing the reinforcing properties of abused drugs. New York: Springer-Verlag, 1987;635-658.

12. Bridges-Webb C, Grounds M. Analgesic use and abuse: the role of caffeine. Med J Aust 1976;20:805.

13. Bruce MS, Lader M. Caffeine abstention in the management of anxiety disorders. Psychol Med 1989;19:211-214.

14. Chait LD. Factors influencing the subjective response to caffeine. Behav Pharmacol 1992;3:219-228.

15. Chait LD, Griffiths RR. Effects of caffeine on human cigarette smoking behavior and subjective response. Clin Pharmacol Ther 1983;34:612-622.

16. Charney DS, Galloway MP, Heninger GR. The effects of caffeine on plasma MHPG, subjective anxiety, autonomic symptoms and blood pressure in healthy humans. Life Sci 1984;35:135-144.

17. Charney DS, Heninger GR, Jatlow PI. Increased anxiogenic effects of caffeine in panic disorders. Arch Gen Psychiatry 1985;42:233-243.

18. Christensen L, Miller J, Johnson D. Efficacy of caffeine versus expectancy in altering caffeine-related symptoms. J Gen Psychol 1991;118:5-12.

19. Collins E, Turner G. A suggestion for reducing the incidence of habitual analgesic consumption. Med J Aust 1973;1:863.

20. Collins RJ, Weeks JR, Cooper MM, Good PI, Russell RR. Prediction of abuse liability of drugs using IV self-administration by rats. Psychopharmacology (Berlin) 1984;82:6-13.

21. Colton T, Gosselin RE, Smith RP. The tolerance of coffee drinkers to caffeine. Clin Pharmacol Ther 1968;9:31-39.

22. Couturier EGM, Hering R, Steiner TJ. Weekend attacks in migraine patients: caused by caffeine withdrawal? Cephalalgia 1992;12:99-100.

23. de Wit H. Preference procedures for testing the abuse liability of drugs in humans. Br J Addict 1991;86:1579-1586.

24. Denaro CP, Brown CR, Jacob P III, Benowitz NL. Effects of caffeine with repeated dosing. Eur J Clin Pharmacol 1991;40: 273-278.

25. Deneau G, Yanagita T, Seevers MH. Self-administration of psychoactive substances by the monkey: a measure of psychological dependence. Psychopharmacologia 1969;16:30-48.

26. Dews PB. Caffeine. Annu Rev Nutr 1982;2:323-341.

27. Dreisbach RH, Pfeiffer C. Caffeine-withdrawal headache. J Lab Clin Med 1943;28:1212-1219.

28. Dworkin SI, Vrana SL, Broadbent J, Robinson JH. Comparing the reinforcing effects of nicotine, caffeine, methylpheindate and cocaine. Med Chem Res 1993;2:593-602.

29. Eddy NB, Downs AW. Tolerance and cross-tolerance in the human subject to the diuretic effect of caffeine, theobromine and theophylline. J Pharmacol Exp Ther 1928;33:167-174.

30. Evans SM, Griffiths RR. Dose-related caffeine discrimination in normal volunteers: individual differences in subjective effects and self-reported cues. Behav Pharmacol 1991;2:345-356.

31. Evans SM, Griffiths RR. Low-dose caffeine physical dependence in normal subjects: dose-related effects. In: Harris LS, ed. Problems of drug dependence 1990. NIDA Research Monograph No. 105, DHHS Publication No. (ADM) 91-1753. Washington, DC: US Government Printing Office, 1991;446.

32. Evans SM, Griffiths RR. Caffeine tolerance and choice in humans. Psychopharmacology (Berlin) 1992;108:51-59.

33. Fennelly M, Galletly DC, Puride GI. Is caffeine withdrawal the mechanism of postoperative headache? Anesth Analg 1991;72: 449-453.

34. Foltin RW, Fischman MW. Assessment of abuse liability of stimulant drugs in humans: a methodological survey. Drug Alcohol Depend 1991;28:3-48.

35. Galletly DC, Fennelly M, Whitwam JG. Does caffeine withdrawal contribute to postanaesthetic morbidity? Lancet 1989;June 10:1335.

36. Garattini S. Caffeine, coffee, and health. New York: Raven Press, 1993.

37. Gilbert RM. Caffeine as a drug of abuse. In: Gibbins RJ, Israel Y, Kalant H, Popham RE, Schmidt W, Smart RG, eds. Research advances in alcohol and drug problems, vol 3. New York: John Wiley & Sons, 1976;49-176.

38. Gilbert RM. Caffeine consumption. In: Spiller GA, ed. The methylxanthine beverages and foods: chemistry, consumption, and health effects. New York: Alan R Liss, 1984;185-213.

39. Gilbert RM. Betel-nut chewing in Toronto. In: The Journal. Toronto: Addiction Research Foundation of Ontario, April 1, 1986;5.

40. Goldberg SR, Henningfield JE. Reinforcing effects of nicotine in humans and experimental animals responding under intermittent schedules of IV drug injection. Pharmacol Biochem Behav 1988;30:227-234.

41. Goldstein A, Kaizer S. Psychotropic effects of caffeine in man. III. A questionnaire survey of coffee drinking and its effects in a group of housewives. Clin Pharmacol Ther 1969;10:477-488.

42. Goldstein A, Kaizer S, Warren R. Psychotropic effects of caffeine in man. II. Alertness, psychomotor coordination, and mood. J Pharmacol Exp Ther 1965;150:146-151.

43. Goldstein A, Kaizer S, Whitby O. Psychotropic effects of caffeine in man. IV. Quantitative and qualitative differences associated with habituation to coffee. Clin Pharmacol Ther 1969;10:489-497.

44. Graham DM. Caffeine--its identity, dietary sources, intake and biological effects. Nutr Rev 1978;36:97-102.

45. Graham HN. Tea: the plant and its manufacture; chemistry and consumption of the beverage. In: Spiller GA, ed. The methylxanthine beverages and foods: chemistry, consumption and health effects. New York: Alan R Liss, 1984;29-74.

46. Greden JF. Anxiety or caffeinism: a diagnostic dilemma. Am J Psychiatry 1974;131:1089-1092.

47. Greden JF, Walters A. Caffeine. In: Lowinson JH, Ruiz P, Millman RB, Langrod JG, eds. Substance abuse--a comprehensive textbook. Baltimore: Williams & Wilkins, 1992;357-370.

48. Griffiths RR, Bigelow GE, Henningfield JE. Similarities in animal and human drug-taking behavior. In: Mello NK, ed. Advances in substance abuse, vol 1. Greenwich, CT: JAI Press, 1980;1-90.

49. Griffiths RR, Bigelow GE, Liebson IA. Human coffee drinking: reinforcing and physical dependence producing effects of caffeine. J Pharmacol Exp Ther 1986;239:416-425.

50. Griffiths RR, Bigelow GE, Liebson IA. Reinforcing effects of caffeine in coffee and capsules. J Exp Anal Behav 1989;52:127-140.

51. Griffiths RR, Bigelow GE, Liebson IA, O'Keeffe M, O'Leary D, Russ N. Human coffee drinking: manipulation of concentration and caffeine dose. J Exp Anal Behav 1986;45:133-148.

52. Griffiths RR, Brady JV, Bradford LD. Predicting the abuse liability of drugs with animal drug self-administration procedures: psychomotor stimulants and hallucinogens. In: Thompson T, Dews PB, eds. Advances in behavioral pharmacology vol 2. New York: Academic Press, 1979;163-208.

53. Griffiths RR, Evans SM, Heishman SJ, Preston KL, Sannerud CA, Wolf B, Woodson PP. Low-dose caffeine discrimination in humans. J Pharmacol Exp Ther 1990;252:970-978.

54. Griffiths RR, Evans SM, Heishman SJ, Preston KL, Sannerud CA, Wolf B, Woodson PP. Low-dose caffeine physical dependence in humans. J Pharmacol Exp Ther 1990;255:1123-1132.

55. Griffiths RR, Lamb RJ, Ator NA, Roache JD, Brady JV. Relative abuse liability of triazolam: experimental assessment in animals and humans. Neurosci Biobehav Rev 1985;9:133-151.

56. Griffiths RR, Woodson PP. Caffeine physical dependence: A review of human and laboratory animal studies. Psychopharmacology (Berlin) 1988;94:437-451.

57. Griffiths RR, Woodson PP. Reinforcing effects of caffeine in humans. J Pharmacol Exp Ther 1988;246:21-29.

58. Guelliot O. Du cafeisme chronique. Union Med Sci Nordest 1885;9:221-240.

59. Henningfield JE, Goldberg SR. Nicotine as a reinforcer in human subjects and laboratory animals. Pharmacol Biochem Behav 1983;19:989-992.

60. Henningfield JE, Lukas SE, Bigelow GE. Human studies of drugs as reinforcers. In: Goldberg SR, Stolerman IP, eds. Behavioral analysis of drug dependence. Orlando, FL: Academic Press, 1986;69-122.

61. Hoffmeister F, Wuttke W. Self-administration of acetylsalicylic acid and combinations with codeine and caffeine in rhesus monkeys. J Pharmacol Exp Ther 1973;186:266-275.

62. Holtzman SG, Finn IB. Tolerance to behavioral effects of caffeine in rats. Pharmacol Biochem Behav 1988;29:411-418.

63. Hughes JR. Clinical importance of caffeine withdrawal. N Engl J Med 1992;327:1160-1161.

64. Hughes JR, Amori G, Hatsukami DK. A survey of physician advice about caffeine. J Subst Abuse 1988;1:67-70.

65. Hughes JR, Higgins ST, Bickel WK, Hunt WK, Fenwick JW, Gulliver SB, Mireault GC. Caffeine self-administration, withdrawal, and adverse effects among coffee drinkers. Arch Gen Psychiatry 1991;48:611-617.

66. Hughes JR, Hunt WK, Higgins ST, Bickel WK, Fenwick JW, Pepper SL. Effect of dose on the ability of caffeine to serve as a reinforcer in humans. Behav Pharmacol 1992;3:211-218.

67. Hughes JR, Oliveto AH, Bickel WK, Higgins ST, Badger GJ. Caffeine self-administration and withdrawal: Incidence, individual differences and interrelationships. Drug Alcohol Depend 1993;32: 239-246.

68. Hughes JR, Oliveto AH, Bickel WK, Higgins ST, Valliere W. Caffeine self-administration and withdrawal in soda drinkers. J Addict Dis 1992;4:178.

69. Hughes JR, Oliveto AH, Helzer JE, Bickel WK, Higgins ST. Indications of caffeine dependence in a population-based sample. In: Harris LS, ed. Problems of drug dependence, 1992. NIDA Research Monograph No. 132, NIH Publication No. 93-3505. Washington, DC: US Government Printing Office, 1993;194.

70. Hughes JR, Oliveto AH, Helzer JE, Higgins ST, Bickel WK. Should caffeine abuse, dependence, or withdrawal be added to DSM-IV and ICD-10? Am J Psychiatry 1992;149:33-40.

71. James JE. Caffeine and health. New York: Academic Press, 1991.

72. Jaffe JH, Jaffe FK. Historical perspectives on the use of subjective effects measures in assessing the abuse potential of drugs. In: Fischman MW, Mello NK, eds. Testing for abuse liability of drugs. NIDA Research Monograph No. 105, DHHS Publication No. (ADM) 89-1613. Washington, DC: US Government Printing Office, 1989;43-72.

73. Kalant H, LeBlanc AE, Gibbins RJ. Tolerance to, and dependence on, some nonopiate psychotropic drugs. Pharmacol Rev 1971;3: 135-191.

74. Kozlowski LT. Effect of caffeine on coffee drinking. Nature 1976;264:354-355.

75. Leathwood PD, Pollet P. Diet-induced mood changes in normal populations. J Psychiatr Res 1983;17:147-154.

76. Lee MA, Cameron OG, Greden JF. Anxiety and caffeine consumption in people with anxiety disorders. Psychiatry Res 1985;15: 211-217.

77. Lee MA, Flegel P, Greden JF, Cameron OG. Anxiogenic effects of caffeine on panic and depressed patients. Am J Psychiatry 1988;145:632-635.

78. Lieberman HR, Wurtman RJ, Emde GG, Coviella ILG. The effects of caffeine and aspirin on mood and performance. J Clin Psychopharmacol 1987;7:315-320.

79. Lieberman HR, Wurtman RJ, Emde GG, Roberts C, Coviella ILG. The effects of low doses of caffeine on human performance and mood. Psychopharmacology (Berlin) 1987;92:308-312.

80. Loke WH. Effects of caffeine on mood and memory. Physiol Behav 1988;44:367-372.

81. Loke WH, Hinrichs JV, Ghoneim MM. Caffeine and diazepam: separate and combined effects on mood, memory, and psychomotor performance. Psychopharmacology (Berlin) 1985;87:344-350.

82. Loke WH, Meliska CJ. Effects of caffeine use and ingestion on a protracted visual vigilance task. Psychopharmacology (Berlin) 1984;84:54-57.

83. Mattila J, Seppala T, Mattila MJ. Anxiogenic effect of yohimbine in healthy subjects: comparison with caffeine and antagonism by clonidine and diazepam. Int Clin Psychopharmacol 1988;3:215-229.

84. McGowan JD, Altman RE, Kanto WP. Neonatal withdrawal symptoms after chronic maternal ingestion of caffeine. South Med J 1988;81:1092.

85. Mumford GK, Evans SM, Kaminski BJ, Preston KL, Sannerud CA, Silverman K, Griffiths RR. Discriminative stimulus and subjective effects of theobromine and caffeine in humans. Psychopharmacology (Berlin) 1994{ewc MVIMG, MVIMAGE,!infinity.bmp} press.

86. Nuotto E, Mattila MJ, Seppala T, Konno K. Coffee and caffeine and alcohol effects on psychomotor function. Clin Pharmacol Ther 1982;31:68-76.

87. Oliveto AH, Bickel WK, Hughes JR, Terry SY, Higgins ST, Badger GJ. Pharmacological specificity of the caffeine discriminative stimulus in humans: effects of theophylline, methylphenidate and buspirone. Behav Pharmacol 1993;4:237-246.

88. Oliveto AH, Hughes JR, Higgins ST, Bickel WK, Pepper SL, Shea PJ, Fenwick JW. Forced-choice versus free-choice procedures: caffeine self-administration in humans. Psychopharmacology (Berlin) 1992;109:85-91.

89. Oliveto AH, Hughes JR, Pepper SL, Bickel WK, Higgins ST. Low doses of caffeine can serve as reinforcers in humans. In: Harris LS, ed. Problems of drug dependence, 1990. NIDA Research Monograph No. 105, DHHS Publication No. (ADM) 91-1753. Washington, DC: US Government Printing Office, 1991;442.

90. Podboy J, Malloy W. Caffeine reduction and behavior changes in the severely retarded. Ment Retard 1977;15:40.

91. Rapoport JL, Jensvold M, Elkins R, Buchsbaum MS, Weingartner H, Ludlow C, Zahn TP, Berg CJ, Neims AH. Behavioral and cognitive effects of caffeine in boys and adult males. J Nerv Ment Dis 1981;169:726-732.

92. Rizzo AA, Stamps LE, Fehr LA. Effects of caffeine withdrawal on motor performance and heart rate changes. Int J Psychophysiol 1988;6:9-14.

93. Robertson D, Wade D, Workman R, Woosley RL, Oates JA. Tolerance to the humoral and hemodynamic effects of caffeine in man. J Clin Invest 1981;67:1111-1117.

94. Robinson JH, Pritchard WS. The meaning of addiction: reply to West. Psychopharmacology (Berlin) 1992;108:411-416.

95. Robinson JH, Pritchard WS. The role of nicotine in tobacco use. Psychopharmacology (Berlin) 1992;108:397-407.

96. Schuster CR, Woods JH, Seevers MH. Self-administration of control stimulants by the monkey. In: Sjoqvist F, Tottie M, eds. Abuse of central stimulants. New York: Raven Press, 1969;339-347.

97. Shi J, Benowitz NL, Denaro CP, Sheiner LB. Pharmacokinetic-pharmacodynamic modeling of caffeine: tolerance to pressor effects. Clin Pharmacol Ther 1993;53:6-14.

98. Silverman K, Evans SM, Strain EC, Griffiths RR. Withdrawal syndrome after the double-blind cessation of caffeine consumption. N Engl J Med 1992;327:1109-1114.

99. Silverman K, Griffiths RR. Low-dose caffeine discrimination and self-reported mood effects in normal volunteers. J Exp Anal Behav 1992;57:91-107.

100. Silverman K, Mumford GK, Griffiths RR. Enhancing caffeine reinforcement by behavioral requirements following drug ingestion. Psychopharmacology (Berlin) 1994;114:424-432.

101. Spiller GA. The methylxanthine beverages and foods: chemistry, consumption, and health effects. New York: Alan R Liss, 1984.

102. Stern KN, Chait LD, Johanson CE. Reinforcing and subjective effects of caffeine in normal human volunteers. Psychopharmacology (Berlin) 1989;98:81-88.

103. Stringer KA, Watson WA. Caffeine withdrawal symptoms. Am J Emerg 1987;5:469.

104. Uhde TW. Caffeine-induced anxiety: an ideal chemical model of panic disorder? In: Asnis GM, van Praag HM, eds. Einstein monograph series in psychiatry. 1994; in press.

105. van Dusseldorp M, Katan MB. Headache caused by caffeine withdrawal among moderate coffee drinkers switched from ordinary to decaffeinated coffee: a 12 week double blind trial. Br Med J 1990;300:1558-1559.

106. Weiss B, Laties VG. Enhancement of human performance by caffeine and the amphetamines. Pharmacol Rev 1962;14:1-36.

107. West R. Nicotine addiction: a re-analysis of the arguments. Psychopharmacology (Berlin) 1992;108:408-410.

108. Winsor AL, Strongin EI. A study of the development of tolerance for caffeinated beverages. J Exp Psychol 1933;16:725-744.

109. World Health Organization. The ICD-10 classification of mental and behavioural disorders, clinical descriptions and diagnostic guidelines. Geneva: World Health Organization, 1992.

110. Yanagita T. Self-administration studies on various dependence-producing agents in monkeys. Univ Michigan Med Center J 1970;36:216-224.

111. Zwyghuizen-Doorenbos A, Roehrs TA, Lipschutz L, Timms V, Roth T. Effects of caffeine on alertness. Psychopharmacology (Berlin) 1990;100:36-39.